Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Critical Analysis: Immunic (NASDAQ:IMUX) and Neuphoria Therapeutics (NASDAQ:NEUP)

Contrasting Neuphoria Therapeutics (NASDAQ:NEUP) & Prenetics Global (NASDAQ:PRE)

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq